Recent preclinical and clinical studies demonstrate the efficacy of Poly ADP-ribose polymerase (PARP) inhibitors such as Olaparib, Talazoparib, Niraparib as monotherapy for patients with breast cancer susceptibility gene 1/2 (BRCA1/2)-mutated ovarian and breast cancers including TNBC [2]. The gene discussed is BRCA1; the disease is breast carcinoma.